Market revenue in 2023 | USD 168.3 million |
Market revenue in 2030 | USD 255.5 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 58.59% in 2023. Horizon Databook has segmented the France liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Initiatives undertaken by various government organizations to enhance research related to HCC is expected to boost market growth in the country. The International Cancer Genome Consortium initiated a project that aimed at identifying rearrangements in HCC and catalog of mutations in somatic genes, which are related to metabolic & alcohol syndrome.
Some government and private organizations that funded the study are Institute National du Cancer, Centre de Resource National Biologique des Tumors Hépatiques, Assistance Pulque - Hopitaux de Paris (AP-HP), Centre National de Genotyped, CHU de Bordeaux, Foundation of Synergies Lyon Cancer, Institute National du Cancer, and Institute National de la Sante’et de la Recherche Medical.
The study stated that different risk factors that result in development of cirrhosis, chronic hepatitis, and HCC in France included viral etiologies through hepatitis B or C infection or exposure to alcohol. Thus, rise in prevalence of diseases causing liver cancer and growth in R&D activities are expected to drive market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into France liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account